BR112020026432A2 - variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso - Google Patents

Info

Publication number

BR112020026432A2

BR112020026432A2 BR112020026432-6A BR112020026432A BR112020026432A2 BR 112020026432 A2 BR112020026432 A2 BR 112020026432A2 BR 112020026432 A BR112020026432 A BR 112020026432A BR 112020026432 A2 BR112020026432 A2 BR 112020026432A2

Authority

BR

Brazil

Prior art keywords

antibody

antibody variant

seq

region

cancer

Prior art date

2018-07-13

Links

• Espacenet
• Global Dossier
• Discuss

• 150000007523 nucleic acids Chemical class 0.000 title claims description 180
• 102000039446 nucleic acids Human genes 0.000 title claims description 126
• 108020004707 nucleic acids Proteins 0.000 title claims description 126
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 116
• 238000000034 method Methods 0.000 title claims description 77
• 201000010099 disease Diseases 0.000 title claims description 66
• 239000000203 mixture Substances 0.000 title claims description 54
• 239000012636 effector Substances 0.000 title claims description 49
• 239000013604 expression vector Substances 0.000 title claims description 41
• 239000008194 pharmaceutical composition Substances 0.000 title claims description 38
• 241000282414 Homo sapiens Species 0.000 claims abstract description 226
• 230000035772 mutation Effects 0.000 claims abstract description 182
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 118
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 445
• 210000004027 cell Anatomy 0.000 claims description 443
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 422
• 206010028980 Neoplasm Diseases 0.000 claims description 157
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 101
• 230000009089 cytolysis Effects 0.000 claims description 77
• 238000003556 assay Methods 0.000 claims description 76
• 230000027455 binding Effects 0.000 claims description 75
• 201000011510 cancer Diseases 0.000 claims description 65
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 63
• 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims description 62
• 239000000427 antigen Substances 0.000 claims description 60
• 230000000694 effects Effects 0.000 claims description 60
• 210000003289 regulatory T cell Anatomy 0.000 claims description 60
• 108091007433 antigens Proteins 0.000 claims description 58
• 102000036639 antigens Human genes 0.000 claims description 58
• 239000004337 magnesium citrate Substances 0.000 claims description 57
• 230000005883 trogocytosis Effects 0.000 claims description 51
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 48
• 238000011282 treatment Methods 0.000 claims description 47
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 35
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 35
• 239000003981 vehicle Substances 0.000 claims description 35
• 206010038111 Recurrent cancer Diseases 0.000 claims description 34
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 32
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 32
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 29
• 101710095468 Cyclase Proteins 0.000 claims description 28
• 230000004044 response Effects 0.000 claims description 27
• 238000006467 substitution reaction Methods 0.000 claims description 27
• 230000001965 increasing effect Effects 0.000 claims description 26
• 238000002560 therapeutic procedure Methods 0.000 claims description 25
• 102000052645 human CD38 Human genes 0.000 claims description 23
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 22
• 230000005764 inhibitory process Effects 0.000 claims description 22
• 201000003444 follicular lymphoma Diseases 0.000 claims description 20
• 210000002966 serum Anatomy 0.000 claims description 18
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 17
• 208000034578 Multiple myelomas Diseases 0.000 claims description 14
• 239000001963 growth medium Substances 0.000 claims description 14
• 238000007747 plating Methods 0.000 claims description 14
• 239000003814 drug Substances 0.000 claims description 13
• 206010057249 Phagocytosis Diseases 0.000 claims description 12
• 206010060862 Prostate cancer Diseases 0.000 claims description 12
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 12
• 230000006037 cell lysis Effects 0.000 claims description 12
• 238000004132 cross linking Methods 0.000 claims description 12
• 238000012217 deletion Methods 0.000 claims description 12
• 230000037430 deletion Effects 0.000 claims description 12
• 230000001419 dependent effect Effects 0.000 claims description 12
• 206010017758 gastric cancer Diseases 0.000 claims description 12
• 230000008782 phagocytosis Effects 0.000 claims description 12
• 201000011549 stomach cancer Diseases 0.000 claims description 12
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
• 230000006907 apoptotic process Effects 0.000 claims description 11
• 238000003780 insertion Methods 0.000 claims description 11
• 230000037431 insertion Effects 0.000 claims description 11
• 230000001939 inductive effect Effects 0.000 claims description 10
• 150000002632 lipids Chemical class 0.000 claims description 10
• 238000004519 manufacturing process Methods 0.000 claims description 10
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 9
• 229960002204 daratumumab Drugs 0.000 claims description 9
• 230000002489 hematologic effect Effects 0.000 claims description 9
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
• 230000002265 prevention Effects 0.000 claims description 8
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
• 208000026310 Breast neoplasm Diseases 0.000 claims description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 201000002528 pancreatic cancer Diseases 0.000 claims description 7
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
• 206010006187 Breast cancer Diseases 0.000 claims description 6
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
• 206010009944 Colon cancer Diseases 0.000 claims description 6
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
• 206010014733 Endometrial cancer Diseases 0.000 claims description 6
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
• 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 6
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
• 206010033128 Ovarian cancer Diseases 0.000 claims description 6
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
• 206010046431 Urethral cancer Diseases 0.000 claims description 6
• 206010046458 Urethral neoplasms Diseases 0.000 claims description 6
• 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 6
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
• 201000010881 cervical cancer Diseases 0.000 claims description 6
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
• 230000003013 cytotoxicity Effects 0.000 claims description 6
• 231100000135 cytotoxicity Toxicity 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• 201000005202 lung cancer Diseases 0.000 claims description 6
• 208000020816 lung neoplasm Diseases 0.000 claims description 6
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
• 201000001441 melanoma Diseases 0.000 claims description 6
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
• 239000002245 particle Substances 0.000 claims description 6
• 201000002510 thyroid cancer Diseases 0.000 claims description 6
• 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 5
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 5
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 5
• 201000007270 liver cancer Diseases 0.000 claims description 5
• 208000014018 liver neoplasm Diseases 0.000 claims description 5
• 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 201000009030 Carcinoma Diseases 0.000 claims description 4
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
• 238000012417 linear regression Methods 0.000 claims description 4
• 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims description 4
• 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
• 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
• 201000001342 Fallopian tube cancer Diseases 0.000 claims description 3
• 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 3
• 229940127089 cytotoxic agent Drugs 0.000 claims description 3
• 229940079593 drug Drugs 0.000 claims description 3
• 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 3
• 201000001343 fallopian tube carcinoma Diseases 0.000 claims description 3
• 230000003902 lesion Effects 0.000 claims description 3
• 230000035899 viability Effects 0.000 claims description 3
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
• 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 2
• 206010027406 Mesothelioma Diseases 0.000 claims description 2
• 235000012000 cholesterol Nutrition 0.000 claims description 2
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 2
• 239000002254 cytotoxic agent Substances 0.000 claims description 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
• 210000004072 lung Anatomy 0.000 claims description 2
• 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
• 230000001394 metastastic effect Effects 0.000 claims description 2
• 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
• 239000002105 nanoparticle Substances 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims description 2
• 206010000830 Acute leukaemia Diseases 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
• 238000009331 sowing Methods 0.000 claims 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 abstract description 32
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 60
• 235000001014 amino acid Nutrition 0.000 description 53
• 208000035475 disorder Diseases 0.000 description 50
• 210000004881 tumor cell Anatomy 0.000 description 50
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 48
• 210000002540 macrophage Anatomy 0.000 description 45
• 239000013598 vector Substances 0.000 description 42
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 38
• 230000000875 corresponding effect Effects 0.000 description 38
• 206010070308 Refractory cancer Diseases 0.000 description 33
• 229940024606 amino acid Drugs 0.000 description 33
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 33
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 32
• 210000003719 b-lymphocyte Anatomy 0.000 description 30
• 210000001744 T-lymphocyte Anatomy 0.000 description 26
• 239000002609 medium Substances 0.000 description 25
• 230000006870 function Effects 0.000 description 24
• 230000001404 mediated effect Effects 0.000 description 24
• 210000001616 monocyte Anatomy 0.000 description 22
• 206010025323 Lymphomas Diseases 0.000 description 21
• 210000000822 natural killer cell Anatomy 0.000 description 21
• 108090000623 proteins and genes Proteins 0.000 description 21
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 20
• 230000000295 complement effect Effects 0.000 description 19
• 238000001727 in vivo Methods 0.000 description 18
• 229940079156 Proteasome inhibitor Drugs 0.000 description 17
• 210000004443 dendritic cell Anatomy 0.000 description 17
• 239000003207 proteasome inhibitor Substances 0.000 description 17
• 230000001225 therapeutic effect Effects 0.000 description 17
• 108060003951 Immunoglobulin Proteins 0.000 description 16
• 239000000872 buffer Substances 0.000 description 16
• 102000018358 immunoglobulin Human genes 0.000 description 16
• 235000018102 proteins Nutrition 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 14
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 14
• 210000004698 lymphocyte Anatomy 0.000 description 13
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 12
• 239000000975 dye Substances 0.000 description 12
• 108020004999 messenger RNA Proteins 0.000 description 12
• 125000003729 nucleotide group Chemical group 0.000 description 12
• 239000002953 phosphate buffered saline Substances 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
• 239000012634 fragment Substances 0.000 description 11
• 210000004379 membrane Anatomy 0.000 description 11
• 239000012528 membrane Substances 0.000 description 11
• 229920001184 polypeptide Polymers 0.000 description 11
• 102000004196 processed proteins & peptides Human genes 0.000 description 11
• 230000009467 reduction Effects 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 210000000170 cell membrane Anatomy 0.000 description 10
• 239000011651 chromium Substances 0.000 description 10
• 210000002865 immune cell Anatomy 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 239000002773 nucleotide Substances 0.000 description 10
• 239000013612 plasmid Substances 0.000 description 10
• 108020004414 DNA Proteins 0.000 description 9
• 230000024203 complement activation Effects 0.000 description 9
• 231100000673 dose–response relationship Toxicity 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 210000005008 immunosuppressive cell Anatomy 0.000 description 9
• 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 8
• 102000053602 DNA Human genes 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 230000002255 enzymatic effect Effects 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 208000030159 metabolic disease Diseases 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 150000001412 amines Chemical class 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 230000000670 limiting effect Effects 0.000 description 7
• 230000000306 recurrent effect Effects 0.000 description 7
• 238000013207 serial dilution Methods 0.000 description 7
• 230000002269 spontaneous effect Effects 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 208000023275 Autoimmune disease Diseases 0.000 description 6
• 241000283707 Capra Species 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 210000001185 bone marrow Anatomy 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 238000002648 combination therapy Methods 0.000 description 6
• 108010047295 complement receptors Proteins 0.000 description 6
• 102000006834 complement receptors Human genes 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 239000003431 cross linking reagent Substances 0.000 description 6
• 229940094732 darzalex Drugs 0.000 description 6
• 238000000684 flow cytometry Methods 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 230000001506 immunosuppresive effect Effects 0.000 description 6
• 229920002477 rna polymer Polymers 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 235000014966 Eragrostis abyssinica Nutrition 0.000 description 5
• 102000009109 Fc receptors Human genes 0.000 description 5
• 108010087819 Fc receptors Proteins 0.000 description 5
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 239000012980 RPMI-1640 medium Substances 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 description 5
• 238000001994 activation Methods 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 206010002022 amyloidosis Diseases 0.000 description 5
• 229910052804 chromium Inorganic materials 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• 208000027866 inflammatory disease Diseases 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 239000013642 negative control Substances 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 5
• 229910052700 potassium Inorganic materials 0.000 description 5
• 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 239000002699 waste material Substances 0.000 description 5
• 102100022002 CD59 glycoprotein Human genes 0.000 description 4
• 101100456536 Caenorhabditis elegans mec-2 gene Proteins 0.000 description 4
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 4
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• 235000006708 antioxidants Nutrition 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• 230000001363 autoimmune Effects 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• 235000013922 glutamic acid Nutrition 0.000 description 4
• 239000004220 glutamic acid Substances 0.000 description 4
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
• 239000000710 homodimer Substances 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 201000008383 nephritis Diseases 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 208000037821 progressive disease Diseases 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 238000009097 single-agent therapy Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
• 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 3
• 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108090000331 Firefly luciferases Proteins 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
• 241001436793 Meru Species 0.000 description 3
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
• 239000004793 Polystyrene Substances 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108091027981 Response element Proteins 0.000 description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 238000003782 apoptosis assay Methods 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 238000004166 bioassay Methods 0.000 description 3
• 229960001467 bortezomib Drugs 0.000 description 3
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
• 229960002438 carfilzomib Drugs 0.000 description 3
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 3
• 108010021331 carfilzomib Proteins 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000002784 cytotoxicity assay Methods 0.000 description 3
• 231100000263 cytotoxicity test Toxicity 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 208000025750 heavy chain disease Diseases 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• 239000000833 heterodimer Substances 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000011630 iodine Substances 0.000 description 3
• 229960003648 ixazomib Drugs 0.000 description 3
• MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 3
• 229960004942 lenalidomide Drugs 0.000 description 3
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
• 238000004020 luminiscence type Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 210000004180 plasmocyte Anatomy 0.000 description 3
• 229920002223 polystyrene Polymers 0.000 description 3
• 229960000688 pomalidomide Drugs 0.000 description 3
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000009118 salvage therapy Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 229960003433 thalidomide Drugs 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• YMOUIASKEISEEG-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.O=C1NC(N)=NC2=C1NC=N2 YMOUIASKEISEEG-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 2
• 208000004736 B-Cell Leukemia Diseases 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
• 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 102000004157 Hydrolases Human genes 0.000 description 2
• 108090000604 Hydrolases Proteins 0.000 description 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
• 102000009490 IgG Receptors Human genes 0.000 description 2
• 108010073807 IgG Receptors Proteins 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102100022338 Integrin alpha-M Human genes 0.000 description 2
• 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
• 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 2
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
• 210000004460 N cell Anatomy 0.000 description 2
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 206010037549 Purpura Diseases 0.000 description 2
• 241001672981 Purpura Species 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• QOTXBMGJKFVZRD-HISDBWNOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)OP(O)(O)=O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 QOTXBMGJKFVZRD-HISDBWNOSA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 2
• 210000000172 cytosol Anatomy 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000000151 deposition Methods 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000000375 direct analysis in real time Methods 0.000 description 2
• 208000016097 disease of metabolism Diseases 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 238000012063 dual-affinity re-targeting Methods 0.000 description 2
• 229960002224 eculizumab Drugs 0.000 description 2
• 210000003162 effector t lymphocyte Anatomy 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 208000007475 hemolytic anemia Diseases 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 206010033675 panniculitis Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 208000031223 plasma cell leukemia Diseases 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 230000036515 potency Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 210000002707 regulatory b cell Anatomy 0.000 description 2
• 238000007790 scraping Methods 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 159000000000 sodium salts Chemical class 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 208000023769 AA amyloidosis Diseases 0.000 description 1
• 229940126670 AB-836 Drugs 0.000 description 1
• 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
• 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
• 208000023761 AL amyloidosis Diseases 0.000 description 1
• 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 201000010000 Agranulocytosis Diseases 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010001766 Alopecia totalis Diseases 0.000 description 1
• 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
• 206010002961 Aplasia Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 235000007652 Arbutus Nutrition 0.000 description 1
• 240000008327 Arbutus unedo Species 0.000 description 1
• 241000945470 Arcturus Species 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 208000012526 B-cell neoplasm Diseases 0.000 description 1
• 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 208000033386 Buerger disease Diseases 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 241000256135 Chironomus thummi Species 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010078596 Complement C5b Proteins 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 208000027534 Emotional disease Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
• 208000033371 Extranodal NK/T-cell lymphoma, nasal type Diseases 0.000 description 1
• 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
• 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
• 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010070531 Foetal growth restriction Diseases 0.000 description 1
• 208000012841 Gamma-heavy chain disease Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 208000008899 Habitual abortion Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 102000007625 Hirudins Human genes 0.000 description 1
• 108010007267 Hirudins Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 208000009388 Job Syndrome Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 244000207740 Lemna minor Species 0.000 description 1
• 235000006439 Lemna minor Nutrition 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000012309 Linear IgA disease Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 239000012515 MabSelect SuRe Substances 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 101710085938 Matrix protein Proteins 0.000 description 1
• 101710127721 Membrane protein Proteins 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 206010027910 Mononeuritis Diseases 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
• 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 206010028424 Myasthenic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 206010028811 Natural killer-cell leukaemia Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 208000007944 Nodular Nonsuppurative Panniculitis Diseases 0.000 description 1
• 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
• 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 206010033885 Paraparesis Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 108091036407 Polyadenylation Proteins 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 208000025237 Polyendocrinopathy Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 201000004854 SAPHO syndrome Diseases 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 206010039361 Sacroiliitis Diseases 0.000 description 1
• 241000239226 Scorpiones Species 0.000 description 1
• 206010039811 Secondary amyloidosis Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000027522 Sydenham chorea Diseases 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• 208000026736 Weber-Christian disease Diseases 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
• 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 208000025751 alpha chain disease Diseases 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 206010001902 amaurosis Diseases 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 238000011091 antibody purification Methods 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• 201000005000 autoimmune gastritis Diseases 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 230000001275 ca(2+)-mobilization Effects 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• ROJMAHHOFDIQTI-UHFFFAOYSA-L calcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydron;piperazine Chemical compound [Ca+2].C1CNCCN1.OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ROJMAHHOFDIQTI-UHFFFAOYSA-L 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 208000011235 central nervous system lupus Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 201000004709 chorioretinitis Diseases 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 238000003501 co-culture Methods 0.000 description 1
• 239000007931 coated granule Substances 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• -1 coatings Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000010612 desalination reaction Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 208000030172 endocrine system disease Diseases 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000030941 fetal growth restriction Diseases 0.000 description 1
• 231100000562 fetal loss Toxicity 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 102000005396 glutamine synthetase Human genes 0.000 description 1
• 108020002326 glutamine synthetase Proteins 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
• 229940006607 hirudin Drugs 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 201000008319 inclusion body myositis Diseases 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 208000037393 large granular lymphocyte leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
• 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
• 210000001939 mature NK cell Anatomy 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 201000000248 mediastinal malignant lymphoma Diseases 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 238000001471 micro-filtration Methods 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000009126 molecular therapy Methods 0.000 description 1
• 208000013734 mononeuritis simplex Diseases 0.000 description 1
• 201000005518 mononeuropathy Diseases 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
• 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
• 208000002040 neurosyphilis Diseases 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 239000011570 nicotinamide Substances 0.000 description 1
• 229960003966 nicotinamide Drugs 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 210000000680 phagosome Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 description 1
• 208000022256 primary systemic amyloidosis Diseases 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 210000000449 purkinje cell Anatomy 0.000 description 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
• 238000001303 quality assessment method Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000005316 response function Methods 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 208000016997 secondary vasculitis Diseases 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 208000002025 tabes dorsalis Diseases 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229960001479 tosylchloramide sodium Drugs 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 238000010865 video microscopy Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1